Viridian Therapeutics, Inc.\DE (VRDN): who owns it and who trades it
As of Nov 16, 2026, VRDN insiders reported 3 open-market sales worth $419K and 1 purchase worth $20M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jennifer Tousignant (Chief Legal Officer), with $419K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Viridian Therapeutics, Inc.\DE
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VRDN
215 funds and institutions reported VRDN shares worth $2.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 16.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 16.60M | 16.11% | $305M | +8% |
| BlackRock, Inc. | 8.55M | 8.30% | $157M | +9% |
| Bellevue Group AG | 6.73M | 6.53% | $124M | +0% |
| Paradigm Biocapital Advisors LP | 6.72M | 6.52% | $124M | +114% |
| Kynam Capital Management, LP | 6.45M | 6.26% | $119M | +176% |
| State Street Corp | 6.12M | 5.94% | $113M | +31% |
| T. Rowe Price Associates | 5.75M | 5.58% | $106M | +79% |
| Fairmount Funds Management LLC | 5.09M | 4.94% | $93.5M | +30% |
| Vanguard Capital Management LLC | 4.58M | 4.44% | $84.1M | +10% |
| Deep Track Capital, LP | 3.59M | 3.49% | $66M | +158% |
| Venrock Adviser, LLC | 3.26M | 3.16% | $59.8M | -16% |
| Wellington Management Group LLP | 3.13M | 3.04% | $57.5M | +2% |
| Vanguard Portfolio Management LLC | 2.75M | 2.67% | $50.6M | +68% |
| Geode Capital Management, LLC | 2.50M | 2.43% | $46M | +7% |
| Avoro Capital Advisors LLC | 2.50M | 2.43% | $45.9M | +67% |
| Baker Bros. Advisors LP | 2.38M | 2.31% | $43.8M | +21% |
| Point72 Asset Management, L.P. | 2.34M | 2.27% | $43M | +626% |
| Caligan Partners LP | 2.19M | 2.13% | $40.3M | – |
| Novo Holdings A/s | 2.13M | 2.07% | $39.2M | +7% |
| Tang Capital Management LLC | 1.79M | 1.74% | $32.9M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VRDN insiders reported $20M of open-market purchases and $419K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | Jennifer Tousignant | Chief Legal Officer | Sale | 10,000 | $24.50 | $245K | Form 4 |
| Aug 19, 2026 | Jennifer Tousignant | Chief Legal Officer | Sale | 4,212 | $24.50 | $103K | Form 4 |
| May 11, 2026 | Fairmount Healthcare Fund II L.P. +2 | Director | Purchase | 1.18M | $17.00 | $20M | Form 4 |
| Dec 31, 2025 | Jennifer Tousignant | Chief Legal Officer | Sale | 2,272 | $31.16 | $70.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Fairmount Healthcare Fund II L.P. | Director, 10% owner | $20M | – | May 11, 2026 |
| Jennifer Tousignant | Chief Legal Officer | – | $419K | Aug 19, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VRDN short interest
High short interest. 15.0% of VRDN shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 19%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17.04M VRDN shares were sold short, 15.0% of the shares outstanding, down 5.3% from the report before. At the average daily volume of 1.88M shares, buying them all back would take about 9.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17.04M | 15.04% | -5% | 1.88M | 9.1 |
| Oct 15, 2026 | 18.00M | 15.89% | +0% | 2.24M | 8.0 |
| Sep 30, 2026 | 17.97M | 15.86% | -8% | 2.03M | 8.9 |
| Sep 15, 2026 | 19.47M | 17.18% | -0% | 1.24M | 15.7 |
| Aug 31, 2026 | 19.51M | 17.22% | +3% | 1.18M | 16.6 |
| Aug 14, 2026 | 19.03M | 16.79% | -1% | 2.10M | 9.1 |
| Jul 31, 2026 | 19.23M | 18.66% | +2% | 1.70M | 11.3 |
| Jul 15, 2026 | 18.92M | 18.36% | +9% | 1.92M | 9.9 |
| Jun 30, 2026 | 17.34M | 16.83% | +15% | 3.12M | 5.6 |
| Jun 15, 2026 | 15.02M | 14.57% | +3% | 1.49M | 10.1 |
| May 29, 2026 | 14.60M | 14.16% | +2% | 1.85M | 7.9 |
| May 15, 2026 | 14.27M | 13.84% | +24% | 4.67M | 3.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Viridian Therapeutics, Inc.\DE company events
Viridian Therapeutics, Inc.\DE filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementThe Company announced positive results of a phase 1 clinical trial in healthy volunteers of VRDN-008, a half-life extended bifunctional FcRn inhibitor, which the Company believes supports a potential best-in-class FcRn-inhibitor profile with every-eight-week subcutaneous dosing. Filing
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 29, 2026AnnouncementThe Company announced that the FDA has approved Lumvoa ™ (veligrotug-vvze) for the treatment of TED regardless of activity or duration. Filing
- Jun 3, 2026VoteReported shareholder vote results. Filing
- May 28, 2026AgreementEnded an important agreement. Filing
- May 26, 2026AgreementViridian Therapeutics, Inc. entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for… Filing
- May 11, 2026AgreementViridian Therapeutics, Inc. completed its public offering of $250 million of its 1.75% Convertible Senior Notes due 2032, including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million of the Notes, solely to cover over-allotments. Filing
- May 5, 2026AnnouncementShared information with investors. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Mar 30, 2026AnnouncementShared information with investors. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Viridian Therapeutics, Inc.\DE financials
Famous investors that hold VRDN
5 of the 50 well-known investors we track reported holding VRDN in their latest 13F filing. The largest position is Steve Cohen's, worth $95.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 4.63M | $95.4M | 0.2% | +98% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.88M | $38.8M | 0.0% | +4459% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 435,700 | $9M | 0.0% | -43% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 103,247 | $2.1M | 0.0% | +66% |
| Israel Englander · Millennium Management | Q3 2026 | 13,841 | $285K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named VRDN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.5% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 7.3% |
| Nov 16, 2026 | T. Rowe Price Associates, Inc. | 13G/A | 4.5% |
| Nov 16, 2026 | Paradigm BioCapital Advisors LP | 13G/A | 7.3% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.3% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.3% |
Questions about Viridian Therapeutics, Inc.\DE (VRDN) stock
Who owns the most VRDN stock?
The largest reported owner of Viridian Therapeutics, Inc.\DE (VRDN) is FMR LLC (Fidelity), with 16.1% of the company. In total, 215 funds and institutions reported holding VRDN at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are VRDN insiders buying or selling?
In the last 12 months, VRDN insiders reported 1 open-market purchase worth $20M and 3 sales worth $419K. The latest trade was on Aug 19, 2026. See every trade.
What is the short interest in VRDN?
As of Oct 30, 2026, 17.04M VRDN shares were sold short, 15.0% of the shares outstanding, down 5.3% from the report before. At the average daily volume of 1.88M shares, buying them all back would take about 9.1 trading days (days to cover). See the history.
Which famous investors hold VRDN?
5 of the 50 well-known investors we track reported VRDN in their latest 13F filing, including Steve Cohen, Ken Griffin, Jim Simons. The largest position is worth $95.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.